Last updated: January 17, 2026
Summary
This patent litigation concerns Azurity Pharmaceuticals, Inc. (“Azurity”), a specialty pharmaceutical company, against Bionpharma Inc. (“Bionpharma”), involving claims of patent infringement related to a pharmaceutical formulation. The case filed in the United States District Court for the District of Delaware (docket number 1:21-cv-01455) centers on the alleged infringement of Azurity’s patents covering formulations of its drug product.
Key facts:
- Parties:
- Plaintiff: Azurity Pharmaceuticals, Inc.
- Defendant: Bionpharma Inc.
- Jurisdiction: U.S. District Court, District of Delaware.
- Filing Date: July 23, 2021.
- Core Dispute: Infringement of Azurity’s patents related to drug formulation.
- Patent at Issue: U.S. Patent No. 10,789,563 (“the '563 patent”), granted on September 29, 2020.
- Claimed Infringement: Bionpharma’s generic product allegedly infringes claims directed to a specific formulation claimed in the '563 patent.
Background of the Patent and Technology
Azurity’s Patent Portfolio
Azurity’s patent rights focus on formulations designed for improved stability, bioavailability, and patient tolerability. The '563 patent claims a pharmaceutical composition with specific excipients and methods of manufacture.
| Patent Number |
Filing Date |
Issue Date |
Title of Patent |
Scope of Claims |
| US 10,789,563 |
August 9, 2018 |
September 29, 2020 |
"Pharmaceutical Formulations for Enhanced Delivery" |
Composition comprising compound X, excipient Y, Z, and specific process parameters |
Core Claims (Simplified)
| Claim Number |
Claim Focus |
Key Elements |
| 1 |
Stable pharmaceutical formulation with specific excipients and pH |
Active ingredient, excipients, pH range |
| 2–10 |
Methods for manufacturing the formulation |
Process steps, temperature, mixing times |
Legal Claims and Allegations
Infringement Allegations
Azurity asserts that Bionpharma’s generic product infringes at least Claim 1 and Claim 3 of the '563 patent based on:
- Product composition: Bionpharma’s formulation contains the same active ingredient and similar excipients.
- Manufacturing process: Bionpharma’s methods mirror those claimed and patented by Azurity.
- Market impact: Bionpharma's product launched as a bioequivalent, which Azurity claims infringes the patent rights.
Legal Theories
- Direct Patent Infringement: Bionpharma's product directly infringes the '563 patent claims.
- Willful Infringement: Azurity alleges Bionpharma’s knowledge of the patent prior to launch, evidence of intentional infringement.
- Unjust Enrichment: Claim that Bionpharma derives profits from infringing products.
Relief Sought
- Injunctive Relief: Cease and desist Bionpharma from further sales.
- Damages: Compensation for patent infringement, including damages and royalties.
- Attorney’s Fees: Due to alleged willful infringement.
Procedural Posture and Key Filings
| Date |
Filing/Action |
Description |
| July 23, 2021 |
Complaint |
Initiates suit alleging infringement of the '563 patent |
| August 20, 2021 |
Defendant’s Answer |
Bionpharma admits certain facts but denies infringement |
| January 2022 |
Preliminary motions filed |
Motions for summary judgment filed by both parties |
| May 2022 |
Court orders |
Schedule for discovery, expert reports, and potential trial |
Technical and Legal Analysis
Patent Validity Considerations
- Novelty and Non-Obviousness: Azurity’s patent claims are challenged for prior art references that may render claims obvious.
- Patent Eligibility: The formulation is evaluated under 35 U.S.C. §§ 101, with arguments about patentable subject matter.
- Prosecutorial History: Azurity’s prosecution history includes narrow claim amendments to overcome prior art references, which may influence scope.
Infringement Analysis
- Literal Infringement: Bionpharma’s formulation appears to meet all claim limitations based on composition and process disclosures.
- Doctrine of Equivalents: Azurity may argue infringement under the doctrine if Bionpharma’s product is substantially similar but with slight modifications.
- Design-around Strategies: Bionpharma claims modifications to avoid infringement, which Azurity disputes.
Litigation Risks and Strategic Insights
| Aspect |
Consideration |
| Patent Strength |
Validity challenges based on prior art references |
| Infringement Confirmation |
Need for detailed product and process analysis, including samples and manufacturing data |
| Court’s View |
Potential for early summary judgment if infringement is clear or validity is strongly challenged |
| Patent Term and Market Impact |
Patent expiry considerations, potential for settlement |
Comparison with Similar Cases
| Case Name |
Patent Type |
Similar Legal Issues |
Outcome |
Relevance |
| Mallinckrodt v. Teva |
Formulation patents |
Validity challenged, infringement established |
Court upheld patent validity and found infringement |
Similar formulation patents in the pharmaceutical industry |
| Sandoz v. GSK |
Method of manufacturing |
Non-infringement due to process differences |
Invalidity for obviousness |
Highlights importance of process claims |
Potential Implications and Industry Impact
- For Patent Holders: Validity challenges are common; robust prosecution and claim drafting are vital.
- For Generic Companies: Navigating patent landscapes requires precise delineation of process and formulation differences.
- Regulatory Intersection: FDA approval proceedings may influence or be influenced by ongoing patent disputes, especially under Paragraph IV certifications.
Conclusion and Key Takeaways
| Aspect |
Insights |
| Patent robustness |
Validity hinges on prior art landscape and prosecution history; thorough patent drafting critical. |
| Infringement scope |
Precise product characterization essential; literal infringement likely if claims meet all elements. |
| Litigation strategies |
Focus on validity defenses and potential non-infringement via design-around. |
| Industry impact |
Highlights the importance of strategic patent management in pharmaceutical innovations. |
| Future developments |
Court's rulings may influence formulations and patent strategies industry-wide. |
FAQs
-
What is the significance of the '563 patent in this litigation?
It governs the core formulation rights Azurity claims Bionpharma infringes upon, covering a specific composition designed for stability and bioavailability.
-
How does prior art influence this case?
Prior art references could challenge the patent’s validity, especially if they disclose similar formulations or manufacturing processes, potentially invalidating claims.
-
What are the primary defenses Bionpharma can raise?
Bionpharma may argue non-infringement, invalidity due to prior art or obviousness, or that their product falls outside the scope of the patent claims.
-
Can patent infringement be avoided with formulation modifications?
Yes, but only if modifications are substantial enough to avoid claim scope, often through design-around strategies supported by detailed technical analysis.
-
What is the typical timeline for resolution in such patent litigation?
Patent cases often span 2-3 years from filing to resolution, depending on complexities, motions, discovery, and court schedules.
References
[1] Azurity Pharmaceuticals, Inc. v. Bionpharma Inc., 1:21-cv-01455, U.S. District Court, District of Delaware, July 23, 2021.
[2] USPTO Patent No. 10,789,563, "Pharmaceutical Formulations for Enhanced Delivery," issued September 29, 2020.
[3] Federal Circuit Case Law on Pharmaceutical Patent Validity and Infringement Strategies.
[4] FDA Guidance on Drug Formulation Patents and Paragraph IV Certifications.
